About Credo Life Sciences Private Limited
Data last updated:
Credo Life Sciences Private Limited is a private limited company based in Shaikpet, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 July 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2014PTC112849. Its GSTIN is 36AAFCC7068Q1ZX (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.5 Cr. It is led by directors including Siva Rama Prasad Aluru (Managing Director) and Kandru Madhavarao.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Shaikpet, Telangana.
As per the financials filed for FY 2024, the company reported a revenue of ₹100.47 Cr, a growth of 22% compared to the previous year. For the same year it recorded a net profit of ₹6.53 Cr (net margin 6.5%) and EBITDA of ₹14.65 Cr (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 31% over five years.
The company has about 204 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Credo Life. As per MCA filings, the company has open charges of ₹32.48 Cr on record. Court records list 1 case involving the company. The company has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Natural Herbs and Formulation Private Limited with revenue of ₹101.16 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website credolife.in.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressFlat No. 1101 Vasavi Sky City. 11th Floor Tower – 1, Telecom Nagar Gachibowli, Shaikpet, Telangana, India – 500081
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Credo Life Sciences Private Limited
The main business activity of Credo Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Credo Life Sciences Private Limited FY 2024 filings available
Credo Life Sciences Private Limited reported revenue of ₹100.47 Cr (up 22% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Credo Life Sciences Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 31% over five years, including 22% growth in the latest year. EBITDA rose 68% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Credo Life Sciences Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹100.47 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹14.65 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹6.53 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Credo Life Sciences Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 6.5% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Credo Life Sciences are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Credo Life Sciences Private Limited
Credo Life Sciences Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Natural Herbs and Formulation Private Limited | ₹101.16 Cr (FY 2025) | •••• | •••• | 62.0% | •••• | Roorkee, Uttarakhand, India |
| Nabros Pharma Private Limited | ₹101.03 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Ahmadabad City, Gujarat, India |
| Instapill Private Limited | ₹100.92 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Bangalore, Karnataka, India |
| Sotac Pharmaceuticals Limited | ₹100.88 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Sanand, Gujarat, India |
| Lake Chemicals Private Limited | ₹100.59 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Bangalore, Karnataka, India |
| Credo Life Sciences Private Limited this company | ₹100.47 Cr (FY 2024) | •••• | •••• | 22.0% | •••• | Shaikpet, Telangana, India |
| Consern Pharma Limited | ₹100.37 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Ludhiana, Punjab, India |
| Addii Biotech Private Limited | ₹100.32 Cr (FY 2025) | •••• | •••• | 59.0% | •••• | Chandigarh, India |
| Medibios Laboratories Limited | ₹100.12 Cr (FY 2023) | •••• | •••• | -2.0% | •••• | |
| Angel Biogenics Private Limited | ₹99.49 Cr (FY 2025) | •••• | •••• | -22.0% | •••• | Rajkot, Gujarat, India |
| Synokem Lifesciences Private Limited | ₹99.46 Cr (FY 2025) | •••• | •••• | 108.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Credo Life Sciences by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Credo Life Sciences Private Limited
Credo Life Sciences Private Limited is audited by K. Nagaraju & Associates for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| K. Nagaraju & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Credo Life Sciences Private Limited
Credo Life Sciences has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kandru Madhavarao Also directs: Credo Pharma Private Limited | Director | 01 Apr 2015 | 11 Years 6 Months | Current |
| Siva Rama Prasad Aluru Also directs: Auctus Life Sciences LLP, Credo Pharma Private Limited | Managing Director | 03 Jul 2014 | 12 Years 3 Months | Current |
| Aluru Vamsi Krishna Also directs: Auctus Life Sciences LLP, Credo Pharma Private Limited | Director | 03 Jul 2014 | 12 Years 3 Months | Current |
Ownership and Shareholding of Credo Life Sciences Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Credo Life Sciences Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Feb 2025 | Indian Bank | ₹1.98 Cr | Open |
| 18 Nov 2024 | Indian Bank | ₹2.15 Cr | Open |
| 03 Jan 2023 | Hdfc Bank Limited | ₹35 Lakh | Open |
| 31 Oct 2016 | Indian Bank | ₹28 Cr | Open |
Total charge records: 4 View all charges
Deals & Funding of Credo Life Sciences Private Limited
Credo Life Sciences Private Limited has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2023 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 3 individuals |
| Oct 2021 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 3 individuals |
| Jun 2021 | Rights issue | ₹2 Cr | Investors: 2 individuals |
| Jun 2017 | Funding round | ₹2.5 Cr | Investors: 4 individuals |
| Jul 2016 | Funding round | ₹2.28 Cr | Investors: 4 individuals |
Full deal history
All 6 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Credo Life Sciences Private Limited
Credo Life Sciences Private Limited has 1 court case on record: 1 where it is another party. All case is disposed. Status as checked on 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Writ petition | Company is another party | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Associated Brands with Credo Life Sciences Private Limited
Credo Life Sciences operates one associated brand: Credo Life. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Supplies specialized pellets and taste-masking granules for global markets. | credolife.in |
Employees and EPFO Compliance at Credo Life Sciences Private Limited
Credo Life Sciences Private Limited has a workforce of 204 employees as of Mar 29, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Credo Life Sciences Private Limited
Credo Life Sciences has one previous CIN (Corporate Identification Number): U24232AP2014PTC094778. The current CIN is U24232TG2014PTC112849, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2014PTC112849 | Current |
| U24232AP2014PTC094778 | Previous |
Recent Activity on Credo Life Sciences Private Limited
Credo Life Sciences Private Limited has 6 board changes on record since 2014: 3 appointments and 3 cessations. The latest: Venkata Narayana Reddy Konda ceased to be Company Secretary on 06 Jul 2021.
2 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Credo Life Sciences Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Credo Life Sciences Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Credo Life Sciences Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Credo Life Sciences Private Limited
Credo Life Sciences has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCC7068Q1ZX | Telangana | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Credo Life Sciences Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Credo Life Sciences Private Limited
Credo Life Sciences is an active private limited company based in Shaikpet, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 July 2014 (12+ years old) and is registered under CIN U24232TG2014PTC112849.
Credo Life Sciences reported revenue of ₹100.47 Cr for FY 2024 (up 22% YoY).
Credo Life Sciences has 3 current directors:
- Siva Rama Prasad Aluru - Managing Director
- Kandru Madhavarao - Director
- Aluru Vamsi Krishna - Director
Credo Life Sciences reported a net profit of ₹6.53 Cr (net margin 6.5%) and EBITDA of ₹14.65 Cr (EBITDA margin 14.6%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Credo Life Sciences is 26% over three years and 31% over five years. In the latest year (FY 2024) revenue rose 22%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Credo Life Sciences is 36AAFCC7068Q1ZX, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Credo Life Sciences is U24232TG2014PTC112849. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Credo Life Sciences has 1 court case on record.
Credo Life Sciences was incorporated on 03 July 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.
Credo Life Sciences has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.
The peers of Credo Life Sciences by revenue are Natural Herbs and Formulation Private Limited, Nabros Pharma Private Limited, Instapill Private Limited, Sotac Pharmaceuticals Limited, Lake Chemicals Private Limited and 5 more, all in the Pharma industry (Formulations).